PLRX - NASDAQ
Pliant Therapeutics, Inc.
$1.17
-0.85%Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live Snapshotplrx
Other Current Liabilities
Last Annual Value
14.44M
3-Year CAGR
26%
5-Year CAGR
26%
10-Year CAGR
%
Pliant Therapeutics, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Pliant Therapeutics, Inc. NASDAQ:PLRX | 14.44M | 16.9% | 22.6% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 6.00M | 10.8% | 3.2% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 25.28M | N/A | 4.1% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 7.91M | 200.4% | 68.1% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 13.61M | 25.2% | 27.6% | -12.1% | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 14.42M | 29.1% | 32.5% | N/A | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 6.41M | 221.9% | 67.9% | N/A | |
 Cibus, Inc. NASDAQ:CBUS | 5.09M | -1.3% | 13.4% | 9.4% | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 6.52M | 129.4% | -15.4% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 8.83M | -7.8% | N/A | N/A | |
 MacroGenics, Inc. NASDAQ:MGNX | 22.23M | N/A | 1.5% | 22.5% |
Pliant Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your PLRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.